CapsoVision, Inc. appears in FDA device records as the applicant for K254230, filed under product code QZF and regulation number 21 CFR 876.1540, Gastrointestinal Capsule Endoscopy Analysis Software Device. The FDA record lists the applicant at 18805 Cox Avenue, Suite 250, Saratoga, California, which is a filing address rather than a verified headquarters. The manufacturer’s own pages describe a commercial-stage medical technology company whose capsule endoscopy system comprises the CapsoCam Plus single-use capsule together with CapsoCloud and CapsoView software. [1][2][8]

The K254230 clearance and its scope

FDA records show K254230 received on December 29, 2025, and decided on September 25, 2026, with decision code SESE and the description Substantially Equivalent. The clearance is a Traditional 510(k) reviewed under the Gastroenterology, Urology advisory committee, with a Summary statement and no third-party review. The device name on the record is CapsoView (CVV); CapsoCloud (CLD), classified as Class II under product code QZF. [1][2]

The FDA clearance letter identifies the trade names as CapsoView (CVV) and CapsoCloud (CLD) and restates the regulation name and Class II designation. The letter also records that CapsoView/CapsoCloud provided a description of verification and validation activities at unit, integration and system level, with test protocols including pass/fail criteria and reports of results. [2]

Documented product components

CapsoVision’s published documentation describes CapsoCam Plus as a capsule endoscopy system with four laterally oriented onboard cameras capturing a 360° panoramic view, and states that the capsule acquires and stores video images in onboard memory while moving through the GI tract. The same documentation describes CapsoCloud as a cloud-based software application for clinical data management and review of capsule endoscopy studies. [5][7][8]

The manufacturer describes CapsoView and CapsoCloud as software within its capsule endoscope system, alongside the CapsoCam Plus single-use capsule. A separate company announcement states that FDA cleared AI Highlights, an AI-assisted reading feature for CapsoCam Plus that identifies frames with suspected small-bowel pathology and presents a curated video within CapsoCloud. [8][9]

Workflow as published by the manufacturer

CapsoVision’s product specifications page describes two primary clinical workflows, including a remote or offsite workflow it calls the most widely used approach in the U.S. That workflow involves capsule ingestion, capsule collection, courier delivery to an authorized CapsoVision Download Center, offsite image download, and cloud-based review using CapsoCloud. [6]

The manufacturer’s site also states that CapsoCam Plus is intended for visualization of the small bowel mucosa in adults and children aged two years and above and may be used as a tool in the detection of abnormalities of the small bowel. These statements are the manufacturer’s published labeling language, not findings from the K254230 record. [5][7]

What the record collection shows

The linked FDA collection for this profile contains one 510(k) record, K254230, and its decision count is one SESE. The record sample is the same single entry, so the sample decision count also stands at one SESE. These figures describe the linked filings as of the snapshot date and are not measures of total company sales, total portfolio or safety performance. [1]